Estudio de extensión de seguridad a largo plazo de OLZ/SAM en sujetos pediátricos con esquizofrenia o trastorno bipolar I

Por invitaciónFase 3ClinicalTrials.gov

ID: NCT04987229Tipo: INTERVENTIONALInicio: 22 de oct de 2021Fin estimado: 1 de sept de 2027

Resumen

Evaluar la seguridad y tolerabilidad a largo plazo de OLZ/SAM en sujetos pediátricos con esquizofrenia o trastorno bipolar I.

Elegibilidad

Edad mínima: 10 YearsEdad máxima: 17 YearsSexo: ALL

Criterios de inclusión

Subject has completed the treatment period in either the ALKS 3831-A311 or the ALKS 3831-A312 study within 10 days of enrolling into this extension study, or subject had terminated early from Study ALKS 3831-A312 due to the clinically significant weight gain criterion.
Subject will benefit from continued therapy with OLZ/SAM per clinical judgment.
Subject is able to be treated on an outpatient basis.
Subject must not be a danger to self or others (per Investigator judgement) and has family support available to be maintained as an outpatient.
Subject's parent(s)/legal guardian(s) is considered reliable by the Investigator and has agreed to provide support to the subject to ensure compliance with study treatment, visits, and protocol procedures.
Subject agrees to abide by the contraception requirements specified in the protocol for the duration of the study.

Criterios de exclusión

Subject poses a current suicide risk as assessed by the Investigator or as confirmed by the baseline Columbia-Suicide Severity Rating Scale by a response of "Yes" to question numbers 4 or 5 with ideation or suicidal behavior since the last visit.
Subject has any finding that in the view of the Investigator or Medical Monitor would compromise the safety of the subject or affect their ability to fulfill the protocol visit schedule or visit requirement.
Subject is currently taking medications that are contraindicated with olanzapine use or exhibit drug-interaction potential with olanzapine
Subject has a positive test for opioids.
Subject has a positive urine pregnancy test, is currently pregnant or breastfeeding, or plans to become pregnant or begin breastfeeding at any point during the study and for 90 days after any study drug administration.

Intervenciones

drug

OLZ/SAM

Olanzapine and Samidorphan fixed dose coated tablet taken once daily

Ubicaciones

Alkermes Investigational Site

Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Alkermes Investigational Site

La Plata, Buenos Aires, Argentina

Alkermes Investigational Site

Buenos Aires, Buenos Aires F.D., Argentina

Alkermes Investigational Site

Mendoza, Mendoza Province, Argentina

Alkermes Investigational Site

Córdoba, Argentina

Patrocinadores

PrincipalAlkermes, Inc.

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

Estudio de extensión de seguridad a largo plazo de OLZ/SA... | EligiMed